Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...

ORLANDO--(BUSINESS WIRE)--Hemophilia patients can be managed with less factor VIII without affecting outcomes and saving significant costs, suggests a study being presented at the World Federation of ...

ATLANTA — Patients with hemophilia A who received a single infusion of an investigational gene therapy called valoctocogene roxaparvovec showed substantially increased levels of the essential blood ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

BERLIN, GERMANY — Patients with hemophilia A who received a gene for coagulation factor VIII (FVIII) packaged in a viral vector had sustained levels of FVIII during 1 year of observation, eliminating ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...

TUCKER, Ga. & ROCKVILLE, Md.--(BUSINESS WIRE)--Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract ...

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) announced positive phase 3 gene therapy trial results in adults with Severe Hemophilia A. The study met all primary and secondary efficacy endpoints in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Over the past ...

For the parents of a child born with haemophilia, the diagnosis comes with both good and bad news. The good news is that the child, at least if he (or rarely, she) is born in the developed world, can ...